pioglitazone has been researched along with Antibody Deficiency Syndrome in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chinen, J | 1 |
| Badran, YR | 1 |
| Geha, RS | 1 |
| Chou, JS | 1 |
| Fried, AJ | 1 |
1 review available for pioglitazone and Antibody Deficiency Syndrome
| Article | Year |
|---|---|
Advances in basic and clinical immunology in 2016.
Topics: Adaptor Proteins, Signal Transducing; Allergy and Immunology; Animals; Clinical Trials as Topic; Hem | 2017 |